Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | TP53 |
| Variant | wild-type |
| Impact List | none |
| Protein Effect | no effect |
| Gene Variant Descriptions | Wild-type TP53 indicates that no mutation has been detected within the TP53 gene. |
| Associated Drug Resistance | |
| Category Variants Paths |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 wild-type | ovarian cancer | predicted - sensitive | Ad.p53-DC vaccine | Phase I | Actionable | In Phase I and Phase II clinical trials, various forms of p53 gene therapy (such as adenoviral-p53) have been shown to be generally safe and have demonstrated clinical efficacy in patients with ovarian cancer (PMID: 12082455; PMID: 19621448; PMID: 21927947; PMID: 15297186; PMID: 12082456). | 15297186 21927947 19621448 12082455 12082456 |
| TP53 wild-type | ovarian cancer | no benefit | p53-SLP vaccine | Phase II | Actionable | In a Phase II trial, p53-SLP vaccine was demonstrated to be safe, well tolerated and to induce p53-specific T-cell responses in ovarian cancer patients; however clinical impact was lacking (PMID: 19621448, PMID: 21328579). | 21328579 19621448 |
| TP53 wild-type | lung non-small cell carcinoma | sensitive | Seliciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Roscovotine (seliciclib) induced substantial apoptosis in non-small cell lung carcinoma cells overexpressing wild-type TP53 in culture (PMID: 22862161). | 22862161 |
| TP53 wild-type | Advanced Solid Tumor | decreased response | Pazopanib + Vorinostat | Phase I | Actionable | In a Phase I study, patients with advanced solid tumor harboring TP53 mutations had increased progression-free survival and overall survival than TP53 wild-type patients after treatment with Votrient (pazopanib) in combination with Zolinza (vorinostat) (J Clin Oncol 32:5s, 2014 (suppl; abstr 2576)). | detail... |
| TP53 wild-type | sarcoma | sensitive | Adavosertib + Gemcitabine | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, the combination of Adavosertib (MK-1775) and Gemzar (gemcitabine) induced cell death in a variety of sarcoma cell lines and inhibited tumor growth in a patient-derived sarcoma xenograft model, independent of TP53 mutational status (PMID: 23520471). | 23520471 |
| TP53 wild-type | colon cancer | sensitive | KRT-232 | Preclinical - Cell culture | Actionable | In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type colon cancer cells in culture (PMID: 26162687). | 26162687 |
| TP53 wild-type | lung cancer | sensitive | KRT-232 | Preclinical - Cell culture | Actionable | In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type lung cancer cell lines in culture (PMID: 26162687). | 26162687 |
| TP53 wild-type | breast cancer | sensitive | KRT-232 | Preclinical - Cell culture | Actionable | In a preclinical study, KRT-232 (AMG 232) activated Tp53 signaling, resulting in growth inhibition of TP53 wild-type breast cancer cells in culture (PMID: 26162687). | 26162687 |
| TP53 wild-type | melanoma | sensitive | KRT-232 | Preclinical - Cell culture | Actionable | In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type melanoma cells in culture (PMID: 26162687). | 26162687 |
| TP53 wild-type | osteosarcoma | sensitive | KRT-232 | Preclinical - Cell culture | Actionable | In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type osteosarcoma cells in culture (PMID: 26162687). | 26162687 |
| TP53 wild-type | liposarcoma | predicted - sensitive | KRT-232 | Phase I | Actionable | In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 100% (10/10) of patients with TP53 wild-type well-differentiated liposarcomas (WDLPS) and 70% (7/10) of patients with TP53 wild-type de-differentiated liposarcomas, with median duration of 3.9 and 2.0 months respectively, and one patient with WDLPS achieved unconfirmed partial response per central evaluation (PMID: 31359240; NCT01723020). | 31359240 |
| TP53 wild-type | lung non-small cell carcinoma | sensitive | KRT-232 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) induced activation of Tp53 target genes and inhibited growth of a non-small cell lung cancer (NSCLC) cell line with wild-type TP53 in culture and inhibited tumor growth in a TP53 wild-type NSCLC cell line xenograft model (PMID: 25567130). | 25567130 |
| TP53 wild-type | multiple myeloma | predicted - sensitive | KRT-232 | Phase I | Actionable | In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 50% (5/10) of patients with TP53 wild-type multiple myeloma (PMID: 31359240; NCT01723020). | 31359240 |
| TP53 wild-type | estrogen-receptor positive breast cancer | predicted - sensitive | KRT-232 | Phase I | Actionable | In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 83.3% (10/12) of patients with TP53 wild-type ER-positive breast cancer (BC), with a median duration of 2.0 months in ER-positive, PR-positive BC, 1.4 months in ER-positive, PR-negative BC, and one patient achieved unconfirmed partial response per central evaluation (PMID: 31359240; NCT01723020). | 31359240 |
| TP53 wild-type | Advanced Solid Tumor | sensitive | KRT-232 | Phase I | Actionable | In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 80% (31/39) of patients with TP53 wild-type advanced solid tumors, with a median duration of 3.1 months (PMID: 31359240; NCT01723020). | 31359240 |
| TP53 wild-type | Advanced Solid Tumor | sensitive | KRT-232 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) induced activation of Tp53 target genes and inhibited growth of several human tumor cell lines with wild-type TP53 in culture and in cell line xenograft models (PMID: 25567130). | 25567130 |
| TP53 wild-type | colon cancer | sensitive | Adavosertib + PF-00477736 | Preclinical | Actionable | In a preclinical study, Adavosertib (MK-1775), in combination with the Chk1 inhibitor, PF-00477736, showed efficacy in various human cancer cell lines (breast, ovarian, colon, prostate), independently of p53 status (PMID: 22713237). | 22713237 |
| TP53 wild-type | medulloblastoma | sensitive | JQ1 | Preclinical | Actionable | In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268). | 24231268 |
| TP53 wild-type | melanoma | sensitive | APR-246 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, APR-246 inhibited growth of TP53 wild-type melanoma cells in 3D culture and in cell line xenograft models (PMID: 21239882). | 21239882 |
| TP53 wild-type | colon cancer | sensitive | SAR405838 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, SAR405838 inhibited growth of TP53 wild-type colon cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672). | 25145672 |
| TP53 wild-type | breast cancer | predicted - sensitive | SAR405838 | Preclinical - Pdx | Actionable | In a preclinical study, SAR405838 (MI-77301) induced p53 signaling and inhibited tumor growth in patient-derived xenograft models of endocrine therapy-resistant breast cancer with wild-type TP53, and induced cell-cycle arrest and inhibited growth of patient-derived endocrine therapy-resistant breast cancer cells in culture (PMID: 27765850). | 27765850 |
| TP53 wild-type | salivary gland adenoid cystic carcinoma | predicted - sensitive | SAR405838 | Preclinical - Pdx | Actionable | In a preclinical study, treatment with SAR405838 (MI-773) resulted in activation of Mdm2 and Tp53 in patient-derived salivary gland adenoid cystic carcinoma (ACC) cells in culture, and led to induction of apoptosis and tumor regression in ACC patient-derived xenograft (PDX) models with wild-type TP53 (PMID: 26936915). | 26936915 |
| TP53 wild-type | prostate cancer | sensitive | SAR405838 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, SAR405838 inhibited growth of TP53 wild-type prostate cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672). | 25145672 |
| TP53 wild-type | acute leukemia | sensitive | SAR405838 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, SAR405838 inhibited growth of TP53 wild-type acute leukemia cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672). | 25145672 |
| TP53 wild-type | acute myeloid leukemia | sensitive | RO6839921 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RO6839921 demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156). | detail... |
| TP53 wild-type | acute myeloid leukemia | predicted - sensitive | Siremadlin | Phase I | Actionable | In a Phase I trial, Siremadlin (HDM201) treatment demonstrated safety and resulted in overall response rates of 4.2% (1/24), 20% (3/15), and 22.2% (6/27) for the recommended expansion doses of 120 mg, 250 mg, and 45 mg, respectively, in patients with TP53 wild-type acute myeloid leukemia (PMID: 34862243; NCT02143635). | 34862243 |
| TP53 wild-type | Advanced Solid Tumor | predicted - sensitive | Siremadlin | Phase I | Actionable | In a Phase I trial, Siremadlin (HDM201) treatment demonstrated safety and resulted in an overall response rate (ORR) of 3.5% (4/115; all partial responses) and disease control rate (DCR) of 36.5% in patients with TP53 wild-type advanced solid tumors, and at the recommended dose for expansion (120 mg), resulted in an ORR of 10.5% (3/29) and DCR of 44.8% in all patients, and a DCR of 83.3% (10/12) in patients with liposarcoma (PMID: 34862243; NCT02143635). | 34862243 |
| TP53 wild-type | Advanced Solid Tumor | predicted - sensitive | Siremadlin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, HDM201 treatment resulted in tumor regression in various cell line xenograft models of Tp53 wild-type tumors (Cancer Res 2016;76(14 Suppl):Abstract nr 4855). | detail... |
| TP53 wild-type | liposarcoma | predicted - sensitive | ALRN-6924 | Case Reports/Case Series | Actionable | In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with liposarcoma (PMID: 34301750; NCT02264613). | 34301750 |
| TP53 wild-type | Merkel cell carcinoma | predicted - sensitive | ALRN-6924 | Case Reports/Case Series | Actionable | In a Phase I trial, ALRN-6924 treatment in a patient with Merkel cell carcinoma resulted in a complete response (PMID: 34301750; NCT02264613). | 34301750 |
| TP53 wild-type | acute myeloid leukemia | sensitive | ALRN-6924 | Preclinical - Patient cell culture | Actionable | In a preclinical study, ALRN-6924 inhibited growth of cells derived from patients with TP53 wild-type acute myeloid leukemia in culture, and inhibited leukemia cell growth, prolonged survival in cell line xenograft models (PMID: 29643228). | 29643228 |
| TP53 wild-type | colorectal cancer | predicted - sensitive | ALRN-6924 | Case Reports/Case Series | Actionable | In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with colorectal cancer (PMID: 34301750; NCT02264613). | 34301750 |
| TP53 wild-type | peripheral T-cell lymphoma | predicted - sensitive | ALRN-6924 | Case Reports/Case Series | Actionable | In a Phase I trial, ALRN-6924 treatment in a patient with peripheral T-cell lymphoma resulted in a complete response (PMID: 34301750; NCT02264613). | 34301750 |
| TP53 wild-type | lymphoma | predicted - sensitive | ALRN-6924 | Phase I | Actionable | In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 59% (24/41), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 20 patients demonstrating stable disease (PMID: 34301750; NCT02264613). | 34301750 |
| TP53 wild-type | Advanced Solid Tumor | predicted - sensitive | ALRN-6924 | Phase I | Actionable | In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 59% (24/41), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 20 patients demonstrating stable disease (PMID: 34301750; NCT02264613). | 34301750 |
| TP53 wild-type | colorectal cancer | predicted - sensitive | MK-8745 | Preclinical - Cell culture | Actionable | In a preclinical study, MK-8745 treatment resulted in apoptosis in Tp53 wild-type colorectal cancer cells in culture (PMID: 22293494). | 22293494 |
| TP53 wild-type | endometrioid ovary carcinoma | sensitive | thioureidobutyronitrile | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment increased Tp53 and Cdkn1a protein levels, resulted in growth inhibition of TP53 wild-type endometrioid ovary carcinoma cells in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221). | detail... |
| TP53 wild-type | liposarcoma | predicted - sensitive | MK-8242 | Phase I | Actionable | In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with advanced solid tumors, particularly those with TP53 wild-type liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and a median progression-free survival in LPS of 237 days (PMID: 28240971). | 28240971 |
| TP53 wild-type | Advanced Solid Tumor | unknown | MK-8242 | Phase I | Actionable | In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with TP53 wild-type advanced solid tumors, particularly those with liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and 75.6% (31/41) of patients achieving stable disease (PMID: 28240971). | 28240971 |
| TP53 wild-type | lung large cell carcinoma | resistant | NSC319726 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of TP53 wild-type lung large cell carcinoma (PMID: 22624712). | 22624712 |
| TP53 wild-type | colon carcinoma | sensitive | MPI-0479605 | Preclinical | Actionable | In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130). | 21980130 |
| TP53 wild-type | lung non-small cell carcinoma | sensitive | CEP-8983 + Cisplatin | Preclinical | Actionable | In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903). | 23428903 |
| TP53 wild-type | colon cancer | sensitive | CPUY201112 | Preclinical | Actionable | In a preclinical study, CPUY201112 reduced viability and induced apoptosis in a colon cancer cell line with wild-type TP53 in culture, and had a limited effect on a colon cancer cell line lacking TP53 (PMID: 26743233). | 26743233 |
| TP53 wild-type | osteosarcoma | sensitive | CPUY201112 | Preclinical | Actionable | In a preclinical study, CPUY201112 reduced viability and induced apoptosis in an osteosarcoma cell line with wild-type TP53 in culture, and had a limited effect on an osteosarcoma cell line lacking TP53 (PMID: 26743233). | 26743233 |
| TP53 wild-type | neuroblastoma | predicted - sensitive | GSK2830371 | Preclinical | Actionable | In a preclinical study, GSK2830371 inhibited proliferation of neuroblastoma cell lines carrying wild-type TP53 in culture (PMID: 25658463). | 25658463 |
| TP53 wild-type | neuroblastoma | predicted - sensitive | Carboplatin + GSK2830371 | Preclinical | Actionable | In a preclinical study, GSK2830371 and Paraplatin (carboplatin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463). | 25658463 |
| TP53 wild-type | neuroblastoma | predicted - sensitive | Doxorubicin + GSK2830371 | Preclinical | Actionable | In a preclinical study, GSK2830371 and Adriamycin (doxorubicin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463). | 25658463 |
| TP53 wild-type | acute myeloid leukemia | sensitive | CTX-1 | Preclinical | Actionable | In a preclinical study, CTX-1 improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273). | 26883273 |
| TP53 wild-type | Advanced Solid Tumor | sensitive | CTX-1 | Preclinical | Actionable | In a preclinical study, CTX-1 induced cell death in several solid tumor cell lines with wild-type TP53 in culture (PMID: 26883273). | 26883273 |
| TP53 wild-type | acute myeloid leukemia | sensitive | CTX-1 + Nutlin-3a | Preclinical | Actionable | In a preclinical study, the combination of CTX-1 and Nutlin-3 resulting in improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273). | 26883273 |
| TP53 wild-type | Advanced Solid Tumor | sensitive | CTX-1 + Nutlin-3a | Preclinical | Actionable | In a preclinical study, CTX-1 and Nutlin-3 worked cooperatively to induce cell death in several TP53 wild-type human tumor cell lines in culture (PMID: 26883273). | 26883273 |
| TP53 wild-type | colorectal cancer | sensitive | Prodigiosin | Preclinical | Actionable | In a preclinical study, Prodigiosin inhibited self-renewal of Tp53 wild-type colorectal cancer cell lines in culture (PMID: 26759239). | 26759239 |
| TP53 wild-type | gastric adenocarcinoma | no benefit | Adavosertib + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, Adavosertib (MK-1775) treatment did not sensitize TP53 wild-type gastric adenocarcinoma cells to radiation therapy in culture (PMID: 32220892). | 32220892 |
| TP53 wild-type | colon cancer | sensitive | Trifluridine | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Trifluridine (FTD) resulted in Tp53-dependent cell-cycle arrest and decreased expression of CyclinB1 and Cdk1 in a Tp53-proficient colon cancer cancer cell line in culture (PMID: 25700705). | 25700705 |
| TP53 wild-type | lung non-small cell carcinoma | sensitive | Cisplatin + KRT-232 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of KRT-232 (AMG 232) and Platinol (cisplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone, resulting in tumor stasis (PMID: 25567130). | 25567130 |
| TP53 wild-type | lung non-small cell carcinoma | sensitive | Carboplatin + KRT-232 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of KRT-232 (AMG 232) and Paraplatin (carboplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone (PMID: 25567130). | 25567130 |
| TP53 wild-type | colon cancer | sensitive | KRT-232 + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type colon cancer cells in culture and in cell line xenograft models (PMID: 26162687). | 26162687 |
| TP53 wild-type | lung cancer | sensitive | KRT-232 + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type lung cancer cell lines in culture and in cell line xenograft models (PMID: 26162687). | 26162687 |
| TP53 wild-type | breast cancer | sensitive | KRT-232 + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type breast cancer cells in culture (PMID: 26162687). | 26162687 |
| TP53 wild-type | melanoma | sensitive | KRT-232 + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type melanoma cells in culture and in cell line xenograft models (PMID: 26162687). | 26162687 |
| TP53 wild-type | osteosarcoma | sensitive | KRT-232 + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type osteosarcoma cells in culture and in cell line xenograft models (PMID: 26162687). | 26162687 |
| TP53 wild-type | colorectal cancer | predicted - sensitive | PD-0325901 + Sapanisertib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically induced apoptosis in TP53 wild-type but not TP53 mutated colorectal cancer cell lines in culture, and demonstrated anti-tumor activity in TP53 wild-type but not TP53 mutated patient-derived xenograft models (PMID: 26272063). | 26272063 |
| TP53 wild-type | fibrosarcoma | sensitive | Pegylated liposomal doxorubicin + RO6839921 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RO6839921 and Doxil combination treatment demonstrated sustained survival benefit in TP53 wild-type fibrosarcoma cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156). | detail... |
| TP53 wild-type | acute myeloid leukemia | sensitive | Cytarabine + RO6839921 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, RO6839921 and Cytosar-U (cytarabine) combination treatment demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156). | detail... |
| TP53 wild-type | lung carcinoma | sensitive | Ceralasertib + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a lung carcinoma cell line harboring wild-type TP53 in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704). | 28062704 |
| TP53 wild-type | salivary gland adenoid cystic carcinoma | predicted - sensitive | Cisplatin + SAR405838 | Preclinical - Pdx | Actionable | In a preclinical study, the combination of SAR405838 (MI-773) and Platinol (cisplatin) resulted in increased Tp53 and Mdm2 expression, and demonstrated improved efficacy over either agent alone in TP53 wild-type patient-derived xenograft (PDX) models of salivary gland adenoid cystic carcinoma, resulting in tumor regression without tumor rebound after cessation of therapy (PMID: 27550999). | 27550999 |
| TP53 wild-type | papillary thyroid carcinoma | sensitive | Alrizomadlin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a TP53 wild-type dedifferentiated papillary thyroid carcinoma cell line treated with Alrizomadlin (APG-115) demonstrated decreased cell viability and induction of cell cycle arrest and apoptosis in culture, and tumor growth suppression and tumor regression in xenograft models (PMID: 28498808). | 28498808 |
| TP53 wild-type | melanoma | sensitive | BI 907828 | Preclinical - Cell culture | Actionable | In a preclinical study, BI 907828 inhibited viability of TP53 wild-type melanoma cell lines in culture (PMID: 39259562). | 39259562 |
| TP53 wild-type | liposarcoma | sensitive | BI 907828 | Preclinical - Cell culture | Actionable | In a preclinical study, BI 907828 inhibited viability of TP53 wild-type liposarcoma cell lines in culture (PMID: 39259562). | 39259562 |
| TP53 wild-type | renal cell carcinoma | sensitive | BI 907828 | Preclinical - Cell culture | Actionable | In a preclinical study, BI 907828 inhibited viability of TP53 wild-type renal cell carcinoma cell lines in culture (PMID: 39259562). | 39259562 |
| TP53 wild-type | Advanced Solid Tumor | predicted - sensitive | BI 907828 + Ezabenlimab | Phase I | Actionable | In a Phase I trial, Ezabenlimab (BI 754091) and BI 907828 combination therapy demonstrated safety in patients with TP53 wild-type advanced solid tumors (n=9), and resulted in a partial response (PR) in 2 patients with biliary tract carcinoma, 1 urothelial carcinoma patient, and 1 myxoid liposarcoma patient, an unconfirmed PR in an intrahepatic cholangiocarcinoma patient, and stable disease in 4 patients with liposarcoma or gastric cancer (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3095; NCT03964233). | detail... |
| TP53 wild-type | meningioma | sensitive | CEP1347 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CEP-1347 induced apoptosis, inhibited viability, and decreased colony formation in a TP53 wild-type meningioma cell line in culture and inhibited tumor growth in a cell line xenograft model (PMID: 37509605). | 37509605 |
| TP53 wild-type | colon carcinoma | sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in TP53 wild-type colon carcinoma cells compared to radiotherapy alone in culture, and wild-type TP53 cells were more sensitive to the treatment combination than TP53 mutant cells (PMID: 29769307). | 29769307 |
| TP53 wild-type | high grade glioma | predicted - sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in TP53 wild-type malignant glioma cell lines in culture, however, the effect was smaller compared to the effects in TP53 mutant cell lines (PMID: 29769307). | 29769307 |